April 06, 2015; 84 (14 Supplement) April 24, 2015
Effect of MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of a Pivotal Phase III Randomized Double Blind Placebo Controlled Study (PL2.002)
Ayman Tourbah, Christine Lebrun Frenay, Gilles Edan, Michel Clanet, Caroline Papeix, Sandra Vukusic, Jerome De Seze, Marc Debouverie, Olivier Gout, Pierre Clavelou, Gilles Defer, David Laplaud, Thibault Moreau, Pierre Labauge, Bruno Brochet, Frederic Sedel, Jean Pelletier
First published April 8, 2015,
Ayman Tourbah
6Department of Neurology, CHU de Reims Reims France
Christine Lebrun Frenay
10Hopital Pasteur Nice France
Gilles Edan
4Neurology CHU de Rennes Rennes France
Michel Clanet
17Service de Neurologie Toulouse France
Caroline Papeix
16Pitie Salpetriere Paris France
Sandra Vukusic
12Hospital Neuro P Wertheimer Lyon France
Jerome De Seze
5Neurology CHU de Strasbourg Strasbourg France
Marc Debouverie
11Hospital Central Nancy France
Olivier Gout
7Fondation De Rothschild Paris France
Pierre Clavelou
9Hopital Gabriel Montpied Clermont Ferrand France
Gilles Defer
8Hopital Cote De Nacre Caen France
David Laplaud
3CHU de Nantes Nantes France
Thibault Moreau
1CHU de Dijon Dijon France
Pierre Labauge
2CHU de Montpellier Montpellier France
Bruno Brochet
13Hospital Pellegrin, Neurology Dept Bordeaux France
Frederic Sedel
15Medday Pharmaceuticals Paris France
Jean Pelletier
14Hospital Timone Adultes Marseille France
Effect of MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of a Pivotal Phase III Randomized Double Blind Placebo Controlled Study (PL2.002)
Ayman Tourbah, Christine Lebrun Frenay, Gilles Edan, Michel Clanet, Caroline Papeix, Sandra Vukusic, Jerome De Seze, Marc Debouverie, Olivier Gout, Pierre Clavelou, Gilles Defer, David Laplaud, Thibault Moreau, Pierre Labauge, Bruno Brochet, Frederic Sedel, Jean Pelletier
Neurology Apr 2015, 84 (14 Supplement) PL2.002;
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 84 no. 14 Supplement PL2.002
Print ISSN:
Online ISSN:
History:
- First Published April 8, 2015.
Copyright & Usage:
Copyright © 2015 by AAN Enterprises, Inc.
Author Disclosures
- Ayman Tourbah6,
- Christine Lebrun Frenay10,
- Gilles Edan4,
- Michel Clanet17,
- Caroline Papeix16,
- Sandra Vukusic12,
- Jerome De Seze5,
- Marc Debouverie11,
- Olivier Gout7,
- Pierre Clavelou9,
- Gilles Defer8,
- David Laplaud3,
- Thibault Moreau1,
- Pierre Labauge2,
- Bruno Brochet13,
- Frederic Sedel15 and
- Jean Pelletier14
- Ayman Tourbah6,
- Christine Lebrun Frenay10,
- Gilles Edan4,
- Michel Clanet17,
- Caroline Papeix16,
- Sandra Vukusic12,
- Jerome De Seze5,
- Marc Debouverie11,
- Olivier Gout7,
- Pierre Clavelou9,
- Gilles Defer8,
- David Laplaud3,
- Thibault Moreau1,
- Pierre Labauge2,
- Bruno Brochet13,
- Frederic Sedel15 and
- Jean Pelletier14
- 1CHU de Dijon Dijon France
- 2CHU de Montpellier Montpellier France
- 3CHU de Nantes Nantes France
- 4Neurology CHU de Rennes Rennes France
- 5Neurology CHU de Strasbourg Strasbourg France
- 6Department of Neurology, CHU de Reims Reims France
- 7Fondation De Rothschild Paris France
- 8Hopital Cote De Nacre Caen France
- 9Hopital Gabriel Montpied Clermont Ferrand France
- 10Hopital Pasteur Nice France
- 11Hospital Central Nancy France
- 12Hospital Neuro P Wertheimer Lyon France
- 13Hospital Pellegrin, Neurology Dept Bordeaux France
- 14Hospital Timone Adultes Marseille France
- 15Medday Pharmaceuticals Paris France
- 16Pitie Salpetriere Paris France
- 17Service de Neurologie Toulouse France
Article usage
Disputes & Debates: Rapid online correspondence
No comments have been published for this article.
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Related Articles
- No related articles found.